Nevertheless, they make some very interesting assumptions about the nature and value of external collaboration and outside knowledge in general. All in all, Discovering the Future: Please feel free to comment and send in feedback, suggestions, and your own experiences with the case.
Similarly, you may think about using the case in a lecture series specializing on markets for technologies, as this element from the case may feature prominently in case discussion. In addition to the closed-open innovation setting, I have also used this case at the onset of a lecture series on Merck open innovation strategic management of technology and innovation either as the very first case, or as the second case following a case defining what strategy is.
The case I usually employ in this context is several years old, but has lost nothing of its relevance: How can we improve? In addition, it comes with a concise, but very useful teaching note HBS-Case While I will not elaborate on these here after all, this is not supposed to be a publicly accessible teaching note!
We are looking forward to hearing from you!
Facebook When teaching about open innovation, I found it much easier to start a clear description of what closed innovation is, and why firms may decide to be closed even when presented with a potentially viable opportunity to open up. The case describes how Merck came to find itself in a very strong position in the early s, at a point in time when the large pharmaceutical firms were increasingly committing themselves to biotechnology, and leaving behind traditional technologies of medicinal chemistry.
I have used this case with advanced undergrads with a strong background in technology and engineering, as well as MBA students, and it has worked equally well with both audiences.
With that knowledge in mind, students in subsequent classes found it much easier to appreciate the difficulties of introducing open innovation to companies, the differences in mindsets required, and the somewhat varying contingencies predicting successful innovative performance.InnoCentive: Our Open Innovation OfferTakes Less Than 60 Days · Only Pay for Success · Challenge Driven · ,+ Solver Network.
Dr. Henry Chesbrough is a co-founder of the Open Innovation Community and created the theory and coined the term "open Innovation." He is Executive Director of the Center for Open Innovation at the Haas School of Business at the University of California, Berkeley, where he is also an adjunct professor.
[email protected] KGaA, Darmstadt, Germany is a multi-year collaboration with touch points across the TED ecosystem. The partnership includes engagements at TED conferences, video content to amplify the organization's untapped ideas and features a TED-curated banner event with a diverse group of speakers from across our community.
In order to solve the world’s problems through science, which is our goal here at Merck, we cannot just work alone.
While our research and development and other internal innovation teams are incredible, we are also always trying to stay open and be aware of new innovations around the world. In order to solve the world’s problems through science, which is the goal of our company, we cannot just work alone.
While our research and development and other internal innovation teams are incredible, we are also always trying to stay open and be aware of new innovations around the world.
Innovation is the lifeblood of Merck. That is why we invested over $ billion in research and development activities in Yet investment alone is not enough to guarantee success.
Drug research is a high-risk and time-consuming process. Only 1 out of everycompounds screened becomes an approved drug.Download